Nasdaq:MODD
Modular Medical, Inc.
A US-based medical device innovator pursuing surgical robotics solutions while managing substantial cash burn through financing activities.
Key Metrics
Investment Thesis
Bull Case
Investors may view MODD as a high-risk, high-reward biotech play positioned in the growing surgical robotics market with proprietary technology ready for deployment. The company maintains a pristine capital structure with negligible debt and ample cash reserves relative to its current liabilities, providing a safety buffer during the development phase. Potential upside exists if the company successfully transitions from cash burn to revenue generation, leveraging its existing intellectual property portfolio.
Bear Case
The stock faces existential risk as net losses have deepened over three consecutive years, with no corresponding revenue growth or profitability on the horizon. Investors should be wary of the company's dependence on external capital markets, as a tightening financing environment could halt operations due to the inability to cover $18.8M in annual deficits. The lack of any reported revenue stream suggests the business model has not yet proven its ability to generate commercial value from its R&D investments.
About Modular Medical, Inc.
Modular Medical, Inc. (MODD) develops and commercializes surgical robotics solutions primarily for minimally invasive procedures in the United States. The company focuses on high-value, proprietary technology designed to enhance surgical precision and patient outcomes across major hospital networks. Despite operating without traditional product revenue in this dataset, the firm leverages significant capital markets activity to fund its research and development efforts.
Analysis
Management Discussion
Management has successfully preserved liquidity through significant financing inflows, resulting in a net change in cash of $3.9M and stable ending cash balances despite a massive $-15.7M operating cash outflow. The company is aggressively investing in its future, with R&D spending at $14.7M consuming the majority of resources while maintaining a minimal debt load. However, the widening annual losses suggest that current commercialization strategies are not yet generating sufficient traction to cover operational expenditures.
Industry Overview
The surgical robotics industry is experiencing rapid growth driven by advancements in minimally invasive techniques and an aging demographic requiring complex procedures. Companies in this sector typically require substantial upfront investment in R&D before achieving market penetration and revenue stability. Regulatory hurdles and the need for extensive clinical trials further extend the timeline to profitability for new entrants.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $13.9M | $17.5M | $19.0M |
| Operating Income | $-13.9M | $-17.5M | $-19.0M |
| R&D | $9.1M | $12.9M | $14.7M |
| G&A | $4.8M | $4.6M | $4.4M |
| Stock-Based Comp | $2.7M | $2.7M | $2.4M |
| D&A | $152.4K | $426.0K | $1.1M |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $975 | $61.0K | $226.0K |
| Pre-Tax Income | $-13.9M | $-17.5M | $-18.8M |
| Income Tax | $1.6K | $2.0K | $2.0K |
| Continuing Ops | $-13.9M | $-17.5M | $-18.8M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-13.9M | $-17.5M | $-18.8M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-13.9M | $-17.5M | $-18.8M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $4.0M | $9.7M | $13.5M |
| Cash & Equivalents | $3.8M | $9.2M | $13.1M |
| Prepaid Expenses | $146.9K | $465.0K | $422.0K |
| Other Current Assets | $100.0K | $0 | $0 |
| Long-Term Assets | $3.2M | $4.1M | $5.2M |
| PP&E (Net) | $1.7M | $3.0M | $4.5M |
| Operating Leases | $1.5M | $1.1M | $765.0K |
| Other LT Assets | $0 | $0 | $0 |
| Total Assets | $7.2M | $13.8M | $18.7M |
| Current Liabilities | $979.3K | $1.5M | $1.3M |
| Accounts Payable | $285.4K | $802.0K | $338.0K |
| Current Leases | $355.2K | $373.0K | $423.0K |
| Other Current Liab | $0 | $0 | $0 |
| Long-Term Liabilities | $1.2M | $817.0K | $393.0K |
| LT Operating Leases | $1.2M | $817.0K | $393.0K |
| Other LT Liab | $0 | $0 | $0 |
| Total Liabilities | $2.2M | $2.3M | $1.7M |
| Shareholders' Equity | $5.1M | $11.5M | $17.1M |
| Paid-In Capital | $53.5M | $77.4M | $101.8M |
| Retained Earnings | $-48.5M | $-65.9M | $-84.8M |
| Total L&E | $7.2M | $13.8M | $18.7M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-13.9M | $-17.5M | $-18.8M |
| Non-Cash Adjustments | $3.1M | $3.3M | $3.7M |
| Working Capital Changes | $-186.4K | $197.0K | $-562.0K |
| Cash from Operations | $-11.0M | $-14.0M | $-15.7M |
| Capital Expenditures | $1.6M | $1.7M | $2.5M |
| Cash from Investing | $-1.6M | $-1.7M | $-2.5M |
| Cash from Financing | $7.4M | $21.1M | $22.1M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-5.3M | $5.4M | $3.9M |
| Beginning Cash | $9.1M | $3.8M | $9.2M |
| Ending Cash | $3.8M | $9.2M | $13.1M |
Frequently Asked Questions
How does Modular Medical, Inc. make money?
The company's operations are characterized by a reliance on equity financing rather than operational revenue streams in the current reporting period, with primary cost drivers being extensive research and development expenditures totaling $14.7M and general administrative costs of $4.4M. Financial structure indicates a focus on asset-light growth supported by paid-in capital of $101.8M against minimal debt obligations.
What are the main risks for MODD?
Severe and widening net losses increasing from -$13.9M in 2023 to -$18.8M in 2025, indicating unsustainable current burn rates without revenue generation. Complete absence of reported revenue or gross profit creates high uncertainty regarding the commercialization timeline of their technology. Heavy reliance on continuous equity issuance for operations as evidenced by $22.1M in financing cash flow versus negative operating cash flow.
What is MODD's competitive advantage?
Proprietary intellectual property in the surgical robotics domain that establishes barriers to entry against established competitors. A robust balance sheet with $13.1M in cash and equivalents providing flexibility for strategic acquisitions or R&D acceleration. Minimal long-term debt exposure with total liabilities of only $1.7M relative to equity.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.